Mandate

Vinge advises Mylan on its offer for Meda

February 12, 2016

Mylan N.V. has announced a recommended public offer to the shareholders of Meda AB (publ) to tender all their shares in Meda to Mylan. The total offer consideration consists of a combination of cash and Mylan ordinary shares. At announcement, the total value of the offer for all Meda shares, including Meda net debt, is approximately SEK 83.6 billion or USD 9.9 billion.
 
In connection with the offer, Mylan has retained Vinge as legal advisor in Sweden. The Vinge team is led by public M&A partners Erik Sjöman and Charlotte Levin and also includes Rikard Lindahl, Anna Edström and Malte Hedlund (on M&A matters), Mikael Ståhl, Louise Brorsson Salomon and Albert Wållgren (on finance matters), Fredrik Gustafsson (on compensation and benefits matters) and Maria Schultzberg (on tax matters).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024